Medicine guide
Dutrebis
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Lamivudine;raltegravir potassium
- Made by
- Merck Sharp Dohme Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Dutrebis is indicated in combination with other anti?retroviral medicinal products for the treatment of human immunodeficiency virus (HIV?1) infection in adults, adolescents, and children from the age of 6 years and weighing at least 30 kg without present or past evidence of viral resistance to antiviral agents of the InSTI (Integrase Strand Transfer Inhibitor) and NRTI (Nucleoside Reverse Transcriptase Inhibitor) classes (see sections 4.2, 4.4 and 5.1).
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Merck Sharp Dohme Limited |
|---|---|
| Active substance | Lamivudine;raltegravir potassium |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J05AR16 · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2015-03-26 |
| Last updated by the regulator | 2017-04-27 |
| EMA product number | EMEA/H/C/003823 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).